PT Tempo Scan Pacific Tbk (TSPC) Fair Value & Analysis
Industrials · ID · Market cap 10.7T IDR
Analysis
PT Tempo Scan Pacific Tbk (TSPC) currently trades at 2,500 IDR, while our model-based Fair Value estimate is 5,000 IDR — implying the stock looks roughly 100.0% undervalued today. We read business quality at 90/100 (high quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
PT Tempo Scan Pacific Tbk engages in the pharmaceuticals, personal care and cosmetics, and distribution services businesses in Indonesia and internationally. The company operates through Pharmaceuticals, Consumer Products and Cosmetics, and Distribution Services segments. It is involved in the pharmaceutical and medical devices trading; manufacture of soaps, herbal products, powder milk, food and beverages, and plastic packaging; and manufacturing and trading of consumer products, cosmetics, and household products. The company sells its products under the Bodrex, Oskadon, Neo rheumacyl, Bodrexin, Contrexyn, Contrex, Oskadryl, Vidoran, Neodulax, Vidoran, Hemaviton, Neo Hormoviton, Polaris, Vitonal, Vitamin IPI, Neo rheumacyl Herbal, Wybert Herbal, Bodrexin Herbal, Herbalax, Marina, Natural Honey, Claudia, Total Care, and ULTIMA II brands. It also engages in the construction and rental of buildings; Trading, fresh milk processing, livestock, and agriculture; cosmetics retailer and e-c…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.